A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)

被引：9

作者：

Hong, David S.

Yaeger, Rona

Kuboki, Yasutoshi

Masuishi, Toshiki

Barve, Minal A.

Falchook, Gerald Steven

Govindan, Ramaswamy

Sohal, Davendra

Kasi, Pashtoon Murtaza

Burns, Timothy F.

Langer, Corey J.

Puri, Sonam

Chan, Emily

Jafarinasabian, Pegah

Ngarmchamnanrith, Gataree

Rehn, Marko

Tran, Qui

Gandara, David R.

Strickler, John H.

Fakih, Marwan

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[5] Mary Crowley Canc Res, Dallas, TX USA

[6] Hlth ONE, Sarah Cannon Res Inst, Denver, CO USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ Cincinnati, Cincinnati, OH USA

[9] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[11] Univ Penn, Philadelphia, PA 19104 USA

[12] Huntsman Canc Inst, Salt Lake City, UT USA

[13] Amgen Inc, Thousand Oaks, CA 91320 USA

[14] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[15] Duke Univ, Sch Med, Durham, NC USA

[16] City Hope Natl Med Ctr, Duarte, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.TPS214

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS214

引用

页数：3